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Introduction: Myotonic dystrophies (DMs) type 1 (DM1) and type 2 (DM2) are autosomal
dominant, multisystem disorders, considered the most common dystrophies in adults.
DM1 and DM2 are caused by dynamic mutations in the DMPK and CNBP genes, respectively.
Methods: Molecular analyses were performed by PCR and themodiﬁed RP-PCR in patients, in
their at-risk relatives and prenatal cases.
Results: The analysis of Polish controls revealed the range of 5-31 CTG repeats for DM1 and
110-228 bp alleles for DM2. Among 318 conﬁrmed probands - 196 (62%) were DM1 and 122
(38%) – DM2. Within DM1families, 10 subjects carried a low expanded CTG tract (< 100
repeats), which resulted in a full mutation in subsequent generations. Two related individ-
uals had unstable alleles–188 bp and 196 bp without common interruptions.
Conclusion: The relative frequencies of DM1/DM2 among Polish patients were 68% and 32%,
respectively, with a relatively high proportion of DM2 mutations (1.6:1).
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DM2, #602668) are autosomal dominant, multisystem dis-
orders, affecting skeletal and smooth muscle, the heart, the
endocrine system and the central nervous system, and are
considered the most common muscle dystrophies in adults.
The clinical picture of DM1 has been divided into four
overlapping phenotypes: congenital form, childhood onset,
adult onset classic and late onset or asymptomatic [1,2]. The
most severe, congenital DM1, generally linked to maternal
transmission, often develops before birth and presents as
hypotonia in infants. Severe generalised weakness and
respiratory insufﬁciency results in high perinatal mortality
[3]. Intellectual disability that causes learning and speech
disabilities is the main feature of childhood-onset DM1. The
core features of adult-onset, classic DM1 comprise distal
muscle weakness and wasting, myotonia and posterior
subcapsular cataracts. Early frontal baldness in males, facial
muscle involvement and typically bilateral mild ptosis are the
characteristic features [4]. Myotonia presents as active,
percussion or electrical myotonia in almost all patients. The
cardiac conduction abnormalities and arrhythmias may cause
early mortality and the central nervous system involvement
with cognitive impairment is also present. Late-onset oligo-
symptomatic patients with DM1 are characterised by milder
clinical phenotype [5].
The phenotype of DM2 is much more variable and milder
than that of DM1. The clinical presentation of DM2 is also
known as proximal myotonic myopathy (PROMM) and is
characterised by marked weakness and the atrophy of the
proximal muscles of the lower limbs, which usually occurs in
individuals older than 40 years [6]. Myotonia and cataracts are
less frequent than in DM1. Even 50% of DM2 patients may not
present with myotonia on clinical examination, and in some,
even electrical myotonia is not detected [7].
Themuscle pain is present in about 50–80% of DM2 patients
and can be the main disabling features of the disease with
potential impact on quality of life [8].
Cramps as well as hypertrophy of calves are common,
whereas facial muscle weakness and ptosis are rare [6,9].
Nonsustained supra- and ventricular tachycardia are themost
common cardiac arrhytmias observed in DM2 patients [10].
Serious cardiac complications were described in a few cases
[11]. Anticipation is rare or absent in patients with DM2, unlike
families with DM1 [12].
Constellation of the histopathological features like central
nucleation, nuclear clumps and type 2 ﬁbres atrophy is
considered as a hallmark of DM2 [13,14].
The worldwide prevalence of DM1 is estimated to be
between 1:5000 and 1:50,000 in the general population. It
ranges from approximately 1:100,000 in some areas of Japan to
1:550 in Northeastern Quebec [15]. DM2 prevalence also seems
to differ in various populations. A recently published genetic
study in the Finnish population showed that the frequency of
the DM2 mutation (1/1830) seems to be much higher than the
frequency of type 1mutations (1/2760) [16]. The DM2 expanded
allele is very rare in Japan and only a single case of DM2 has
been reported to date in this population [17].The molecular defect causing DM1 and DM2, involves the
expansion of microsatellite repeats in the respective genes. The
expansion of CTG repeats in the DM1mutation is located within
theuntranslated30 regionofDMPK (dystrophiamyotonicaprotein
kinase) gene (19q13.2-q13.3). According to the International
Myotonic Dystrophy Consortium (IDMC) in 2000 [18], the range
of CTG repeats in a normal alleles is between 5 and 34. Mutable
normal alleles (premutation) contain 35–49 CTG repeats and
increased meiotic instability may result in the further expansion
to the pathogenic range (≥50 CTG repeats). Abnormal CTG repeat
lengths are in the range of 50–150 in the mild form, 100–1000 in
the classic form and can reach several thousand repeats in
infants with the congenital form of DM1 [3]. The pathomechan-
ism of the dynamic mutation leading to multi-organ symptoms
acts at the RNA level as an RNA-toxic gain-of-function mutation
resulting in the abnormal splicing of different genes [19–23].
The DM2-associated gene CNBP (3q13.3-q24) codes for a
CCHC-type zinc ﬁnger, nucleic acid binding protein and
contains a complex repeat motif – (TG)n(TCTG)n(CCTG)n – in
the intron 1; these three repeat tracts are present in both
normal and expanded alleles. Moreover, the CCTG tract in
normal alleles contains tetranucleotide interruptions (TCTG or
GCTG). DM2 results from the expansion of the pure (CCTG)n
repeats. The size of the complex in normal alleles ranges from
104 to 176 bp and is usually reported in base-pair lengths
because of its polymorphic TG and TCTG repeat tracts [24,25].
The characteristic feature of the DM2mutation is pure (CCTG)n
expansionwith 75–11,000 repeats and loss of interruptions. The
pathogenic mechanism of CCTG expansion causes RNA gain-
of-function toxicity leading to the formation of ribonuclear foci
and splicing disturbances. The clinical picture of DM2may also
result from aberrant CNBP expression, decreased both on the
mRNA and the protein levels, which may be a consequence of
multiple factors, for example, the inappropriate pre-mRNA
processing of the CNPB mutant allele [26,27].
The aim of this study was to investigate the genetic status
of a large group of patients with a clinical diagnosis of DM and
to assess the relative proportions of DM1 and DM2 in Polish
patients.
2. Material and methodsThe study group consisted of 742 patients with an initial
diagnosis ofmyotonic dystrophy type 1 or type 2. Additionally,
133 individuals and prenatal cases were tested as asymptom-
atic members of the families, leading to a total number of 875
individuals genetically evaluated for the presence of DM1 and
DM2.
The patients referred for DM1 genetic testing met the main
inclusion criteria established by Harper [28] which included
distal muscle weakness and atrophy, myotonia, facial muscle
involvement and cataracts. The clinical criteria for DM2
genetic testing were consistent with the recommendation
presented by Udd at al. in 2006 at an ENMC meeting [6] and
were extended during the study according to modiﬁcations
published in 2011 [29].
16 patients were genetically tested because of the result of
muscle biopsy characteristic for DM2: central nucleation, nuclear
clumps and type 2 muscle ﬁbres atrophy were observed.
Fig. 1 – The frequency of DMPK alleles in a Polish control
group composed of 181 healthy individuals (n = 362
chromosomes).
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ethnicity aged 18–98 years, with neither neurologic normuscular
complaints. Typically, they were recruited from healthy spouses
of patients (other than DM patients) visiting the Genetic
Counselling Unit and presented no apparent disorders.
The informed consent for the genetic testing was obtained
from all tested individuals. The study protocol was approved
by the appropriate Bioethics Committee.
DNA samples were extracted from the peripheral blood
using the standard phenol/chlorophorm method described
elsewhere [30,31] or automated isolation with Magna Pure
Compact Nucleic Acid Isolation Kit I – Large Volume (Roche
Diagnostics, IN, US) according to the manufacturer recom-
mendations. Testing for CTG/CCTG repeats were performed
via PCR reactions with primers according to Brook et al. [32]
and Liquori et al. [24]; the reverse primer was ﬂuorescently
labelled. The exclusion of the disease was made if two normal
alleles were present.
For DNA samples in which only one allele was observed
(homozygous individuals) a repeat primed PCR (RP-PCR)
reactionwas performedwith a reverse primer, a primer speciﬁc
to the CTG repeats and a P3R tail-speciﬁc primer [33]. The RP-
PCR testing for the DM1 locus was performed in two directions
as recommended by EMQN to avoid false negative tests results.
For the DM2 molecular analysis, the RP-PCR reaction [34] was
performed with a reverse labelled primer, a primer speciﬁc to
CCTG repeats and a P3R tail-speciﬁc primer: RP-DM2P4CCTG50-
TAC GCA TCC CAG TTT GAG ACG CCT GCC TGC CTG-30.
The RP-PCR method detects large expansions and is a
qualitative technique only because it does not reveal the exact
number of repeats both for DM1 and DM2.
All PCR products were separated on 4% polyacrylamide gels
with theautomatic sequencerABI PRISM377 (AppliedBiosystems,
CA, US). The length of products was established by comparison
with the internal size standard (GeneScan 500 TAMRA).
The analysis for the single nucleotide polymorphism (SNP)
rs1871922 was performedwith primers described by Bachinski
et al. [35], but conditions were modiﬁed by the authors. The
172 bp fragment obtained in the PCR reaction was digested
with the Hae III restriction enzyme. Within the amplicon, one
restriction site is present that yields two products (65 and
107 bp). The presence of another restriction site depends on
the presence or absence of a C nucleotide. If the allele with the
C nucleotide is present, the restriction digestion yields 3
products (65, 37 and 70 bp), whereas the A allele yields two
products. Products labelled ﬂuorescently were separated in 4%
polyacrylamide gel in the ABI PRISM 377 sequencer.
The sequencing of DM2 alleles was performed with the
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Bio-
systems) and capillary electrophoresis in POP 7 polymer.
A custom NGS (Next Generation Sequencing) ‘‘Myotonia’’
panel including 9 genes: CACNA1S, CLCN1, HINT1, HSPG2,
KCNJ18, KCNJ2, KCNJ5,MBNL1 and SCN4Awas applied to screen
for causative variants in the patient with CCTG repeats
instability in the DM2 locus. The Agilent SureSelectQXT Target
Enrichment kit was used to generate the libraries and
sequencing performed on MiSeq Illumina platform.
The CLCN1 gene variants identiﬁed in the patient were
evidenced by Sanger sequencing also inher affected father and
healthy mother.Statistical analysis was performed using Statistica v. 6.1.3. Results
3.1. Molecular analysis of DMPK gene in healthy controls
and patients affected with DM
The analysis of the CTG allelic distribution in theDMPK gene in
a Polish control group of 181 individuals revealed a range of 5–
31 CTG repeatswith themost frequent allele with 5 CTGs (36%)
and a heterozygosity of 80% (Fig. 1). The distribution of DM1
alleles was in accordance with the Hardy–Weinberg equilibri-
um (p = 0.049).
Molecular tests in the studied group of 875 individuals
provided positive results for either DM1 or DM2 in 588 cases:
DM1 – 400 subjects (including predictives) from 196 pedigrees
and DM2 – 188 subjects (including 41 predictives) from 122
pedigrees.
In 8 of 16 patients tested for DM2 on the basis of
characteristic pattern of muscle biopsy the test was positive.
3.2. Low expanded alleles of DMPK gene (DM1)
Among 400 DM1 subjects, we found 17 from 16 families (mean
age at examination was 54.7 years) with small range of
expanded alleles (50–97 CTG) (Table 1). 10 of these were
asymptomatic persons (with 50, 55, 74, 75, 75, 84, 88, 88, 90 and
97 CTG repeats) and 7 individuals showed mild form of the
disease and classic DM1 phenotype (41.2%). The transmission
was paternal in 11andmaternal in 6 cases. All the 17mentioned
subjects produced offspring with full DM1 mutation
3.3. Two rare familial cases of coexistence of premutation
and full range mutation in DMPK locus
In 2 out of 197 pedigrees, we came across the coexistence of a
DM1premutation and a fullmutation. In the ﬁrst case a patient
aged 23 affected with congenital form of the DM1 had two
alleles: one with full mutation inherited from the affected
mother and the second one with premutation of 40 CTG
repeats inherited from the healthy father. In the second case (a
patient aged 16 affected with congenital form of DM1), a full
mutationwas transmitted by the father and premutation of 40[(Fig._1)TD$FIG]
Table 1 – Clinical characteristics of patients with low expanded alleles in DMPK gene.
Patients no. Date of birth Age at examination CTG number Clinical symptoms
1. 1946 58 50 Asymptomatic
2. 1939 73 54 Symptomatic (symptoms unknown)
3. 1948 59 55 Asymptomatic
4. 1958 46 58 Arrhythmia
5. 1944 60 63 EMG – slight abnormalities
6. 1954 51 65 Cataract at 46 years
7. 1965 46 74 Asymptomatic
8. 1961 47 75 Asymptomatic
9. 1965 43 75 Asymptomatic
10. 1958 53 80 Cataracts
11. 1950 58 80 Myocardial infarction
12. 1967 46 84 Asymptomatic
13. 1951 60 85 Myotonia, distal weakness of upper limbs
14. 1961 45 88 Asymptomatic
15. 1937 66 88 asymptomatic
16. 1946 63 90 Asymptomatic
17. 1954 57 97 Asymptomatic
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attention in genetic counselling. In both mentioned families
the alleles of 40 CTG reminded stable at transmission.
3.4. Molecular investigation of CNBP gene in healthy
controls and patients affected with DM2
For the complex repeatmotif (TG)n(TCTG)n(CCTG)n in the CNBP
gene, the control range established in our study was 110–
158 bp. One exception was an individual, aged 92 years, with
one allele of 228 bp, apparently unaffected female. An allele of
140 bp was found to be the most common (22%) and the CNBP
gene heterozygosity was found in 89% (Fig. 2 and Table 2). The
distribution of DM2 alleles was in accordance with the Hardy–
Weinberg equilibrium with p = 0.999.
The presence of expanded alleles in the CNBP gene was
found in 188 of the subjects from 122 families. Moreover, 41
predictive tests were performed with 22 positive results.
3.5. Atypical alleles size in myotonic dystrophy type 2 and
SNP analysis
Interestingly, among the patients examined towards DM2 we
identiﬁed a family with CCTG repeats instability – a 196 bp
fragment in the affected girl and a 188 bp fragment in her[(Fig._2)TD$FIG]Fig. 2 – The frequency of CNBP alleles in a Polish control
group composed of 181 healthy individuals (n = 362
chromosomes).father, i.e., they exhibited instability with an 8 bp expansion (2
tetranucleotide repeats) during the father-to-daughter trans-
mission.
These alleles were clearly above the normal range of 104–
176 bp according to Liquori et al, but below the range of 75–
11,000 CCTG repeats that was previously observed and
considered to be pathogenic in patients with DM2 [24].
A patient with 188 bp allelewas a 33 yearmale complaining
of cramps and muscle stiffness and myalgia after exercises
from about 20 years of age. His neurological examination was
normal except of percussion myotonia. EMG revealed some
myotonic discharges and neurogenic changes in vastus lateral
muscle. The CK level was mildly elevated and dyslipidemia
was observed. A 24-h ECG revealed supraventricular arrhyth-
mias. His 7-years-old daughter with myotonia. complained of
stiffness of the lower limbs and difﬁculties in initiating
walking from about 3 years of age and her EMG showed
myotonic discharges. Her phenotype met the criteria of
nondystroﬁc myotonia. As the father presented a mild
myotonia with multisystemic disorders, the test for DM1
and DM2 were performed in both of them.
The sequencing analysis in both patients revealed the
following structure:Father NA (normal allele):
[TG]19[TCTG]11[CCTG]5GCTGCCTGTCTG[CCTG]5 (134 bp).
Father AA (abnormal allele): [TG]16[TCTG]9[CCTG]30
(188 bp).
Daughter NA: [TG]21[TCTG]9[CCTG]5GCTGCCTGTCTG
[CCTG]7 (138 bp).
Daughter AA: [TG]16[TCTG]9[CCTG]32 (196 bp).
Considering the relatively high frequency of DM2 in Poland
and the presence of atypical alleles of CNBP gene in patients
and in one control subject (228 bp), the analysis of SNP
rs1871922was carried out. The 26 patientswith DM2with a full
mutation andaswell as 2 abovementioned cases, possessed at
least one C allele known to be linked to the European founder
mutation [35]. The genotypes frequency: A/C – 50% and C/C –
50% were observed in the patient group. In 36 individuals with
Table 2 – Frequencies of particular alleles of CNBP gene with the length of combined motif (TG)n(TCTG/CCTG)n in Polish and
other control populations.
Control group, origin
(no. of chromosomes)
CNBP gene Reference
The length of the
(TG)n(TCTG/CCTG)n
tract (range)
Most frequent allele Heterozygosity (%) Alleles > 160 bp (%)
European Caucasians (973) 92–190 bp 132 bp n.d. 1.8% [38]
African Americans (180) 95–212 bp 126 and 132 bp n.d. 8.3% [38]
European Caucasians (1360) 104–176 bp 140 bp 89 0.22% [25]
Polish (362) 110–228 bp 140 bp 89 0.27% This study
n.d. – not determined.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 7 3 6 – 7 4 2740normal CCTG repeats number the following genotypes were
detected: A/A – 19.4%, A/C – 69.5%, C/C – 11.1%.
NGS approach revealed two known pathogenic variants in
the CLCN1 gene in the affected female c.[1701C>A]; p.
(Asn567Lys) known as dominantly inherited and c.[2680C>T];
p.(Arg894Ter) recognised as recessive one. In the affected father
c.[1701C>A]; p.(Asn567Lys) variant was found and the mother
is a carrier of the c.[2680C>T]; p.(Arg894Ter) variant.
By analysing medical ﬁles and pedigrees with conﬁrmed
DM1 or DM2 patterns, we were able to determine that there
were 89 familial cases of DM1 and 48 familial cases of DM2 as
well as 107 and 74 sporadic cases of DM1 and DM2,
respectively. It is notable that family history was not always
available before the molecular conﬁrmation of DM1 or DM2.
4. DiscussionThe frequencies of the particular alleles of the DMPK gene
obtained in the control group are similar to frequencies reported
in other populations. The range of 5–31 CTG in the DMPK gene is
comparable to the range observed in the European descent
populations: (5–27 CTG; 5–30; 5–35) [32,36,37]. The 5 CTG allele in
DMPK gene was the most common in all the studies.
Liquori et al. were theﬁrst to report the structure of the tract
containing polymorphic CCTG repeat in CNBP gene and its
range of 104–176 bp [24] in a group of 680 controls. Other
published analyses of two control groups, European Caucasian
and African American revealed the length ranged from 92–190
and 95–212 bp, respectively. Alleles greater than or equal to
160 bpweremore common inAfricanAmericans (8.3%) than in
European Caucasians (1.8% or 0.22%) [24,38]. Our results,
obtained from 181 controls, revealed a range of 110–228 bp; the
228 bp allele is clearly above the ranges published to date
(Table 2). However, if we eliminate this single, particularly
large, allele (228 bp), the range of (TG)n(TCTG/CCTG)n in Polish
population is quite low: 110 – 158 bp (Fig. 2). The presence of
large alleles (above 160 bp – 0.27%) in the Polish population
seems to be less common than in other control groups
reported in the literature, however, the prevalence of DM2,
surprisingly seems to be relatively high. It seems that beside
the microsatellites number, distribution pattern and location
of interruptions within themicrosatellite tracts of long normal
alleles, are the major genetic risk factors contributing to the
loss of stability and the occurrence of diseases caused by
dynamic mutations, as was shown for SCA1 and SCA2 [39].Therefore, studies of larger control groups are required to
evaluate the frequency and structure of large alleles in order to
evaluate them as a potential reservoir for DM2 mutations.
The high proportions of heterozygosity in DM1 and DM2 in
Polish healthy individuals (80% and 89%, respectively) is
similar to those reported by Liquori et al. [24] but higher than in
other studies – 75% (DM1) [33] or 81% (DM2) [38].
Considering that thenormalCNBP alleles size ranges between
104 and 176 bp and the known pathogenic range is between 75
and 11,000 repeats, there is a ‘‘gap’’ range of 177–372 bp that
corresponds to approximately 27–74 CCTG repeats [40]. In the
study of Polish control group, except the longest allele of 228 bp
found in theunaffected92-year-oldwoman,noallele longer than
158 bp has been identiﬁed. The same 228 bp allele was observed
togetherwithanexpansionof 3400CCTG repeats in a59-year-old
Japanese woman who suffered from progressing weakness of
four limbs, diabetes mellitus and cataracts [41].
Interestingly, among our study patients, we have detected
two CNBP alleles of atypical size belonging to the ‘‘gap’’ range
(188 and 196 bp) in an affected father and daughter.
Sequencing of their CNBP alleles revealed a loss of
interrupting repeats in both large alleles and uninterrupted
tracts of CCTG in the father and the daughter of 30 and 32
CCTG, respectively, which also conﬁrms meiotic instability
during paternal transmission of 188 bp allele. Studying the
length and structure of normal chromosomes, Bachinski et al.
distinguished the class of uninterrupted alleles into two
subtypes: premutation range (166–186 bp corresponding to 24–
32 CCTG) and small fullmutation (276–300 bp corresponding to
55–61 CCTG repeats) [38].
After completing the two described projects a new research
project on non-dystrophic myotonias allowed us to perform
NGS screening of genes related to non-dystrophicmyotonias in
this family. Themore severely affected female is the compound
heterozygote, carrying the dominant variant c.[1701C>A]; p.
(Asn567Lys) as the result of the transmission fromthe relatively
mildly affected father and recessive variant c.[2680C>T]; p.
(Arg894Ter) from the asymptomatic mother-carrier.
Other causes of nondystrophic myotonias were excluded.
Obviously the daughter's phenotype ismainly attributed to the
CLCN1 gene mutations and it is difﬁcult to predict a role of
unstable allele of CNBP gene as a phenotype modiﬁer in this
case. A relation between the phenotype of the father, who
carries the dominant mutation in the CLCN1 gene and an
unstable allele of CNBP is not evident. A further observation of
the patients is necessary to draw ﬁnal conclusions.
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interpreted as geneticmodifying factors of the DM2 phenotype
were reported in Finland, Germany and Norway [42–44].
Moreover, SNP rs1871922 analysis showed the genotype A/
C or C/C in all 24 of thosewith a full DM2mutation aswell as in
the 2 above-mentioned cases, which is in accordance with the
data reported by Bachinski et al. [35] Allele C seems to be
common, but usually segregates with themutation and shows
a different frequency in controls.
In our large group of patients, with both DM1 and DM2, 318
pedigrees were identiﬁed. The relative frequencies of DM1 and
DM2 in the investigated material of unrelated cases were 61.6%
and 38.4%. The Polish control group was not numerous enough
to estimate the population frequency of DM1 and DM2
mutations. Other studies were undertaken for other different
populations and revealed conﬂicting results. The prevalence of
DM1 in the European population was estimated at 1/25,000,
whereas the prevalence in the French-Canadian population in
the Quebec province was much higher – 1/514 [45]. The lower
prevalence of DM1 in the Japanese, Albanian, Egyptian and
Italian population is thought to be associated with the low
frequency of the ‘‘at risk’’ alleles, or more than 19 CTG repeats
[37,46,47]. The frequency of myotonic dystrophy in the Finnish
population seems to be much higher than previously reported
estimates, which were 1/8000 for DM1 and DM2 together, and a
mutation rate of DM1 andDM2 at 1/2760 and 1/1830, respectively
[16]. The proportion of DM2 cases identiﬁed in our study is higher
than expected according to the length of normal alleles in
healthy controls. Moreover, because of a milder clinical
phenotype, DM2 may be less frequently recognised or perhaps
even misdiagnosed [12]. Clinicians should also consider the
possibility that patients with DM2may often present as isolated
cases. In our study, the mean number of affected subjects per
pedigree was 1.3 for DM2 and 1.6 for DM1.
Our study, and the results of the study by Suominen et al.
[16], suggest that DM2 seems to be more prevalent than
previously expected and a detailed investigation is essential to
explore the whole spectrum of the disease's clinical presenta-
tion.
The presence of low expanded DM1 alleles detected in 17
individuals suggests that some patients may remain asymp-
tomatic or present with very subtle clinical symptoms that may
not be recognised. Patients with a low number of CTG
expansions were previously described as being relatively
frequent in the Canadian population; most of them had 50–99
CTG repeats and showed no clinical symptoms except for
cataracts [5]. Out of the 17 individuals described here with 50–97
CTGs, 6hadmild symptomsor conditionsnotnecessarily related
to the detected mutation (Table 2). The clinical status of these
individuals may depend on the age at examination, i.e., the
clinical expression can be detected mainly in elderly carriers.
The diagnostic protocol for molecular testing to identify
DM1 and DM2 in a group of 875 individuals (patients,
predictives and prenatal) included a combination of regular
PCR and RP-PCR that tested for normal and expanded alleles,
as well as premutation or the expansion of 50–100 CTG repeats
[30]. This approach represents a valuable tool formutation and
premutation detection in DM1 and DM2 patients and asymp-
tomatic carriers.Conﬂict of interestNone declared.
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